December 14, 2018
Add to Twitter
English | عربي
Takeda to Present Positive Data from TOURMALINE-MM3, First Pivotal Phase 3 Placebo Controlled Trial Evaluating Proteasome Inhibitor Treatment in Maintenance Setting
– Maintenance Therapy with NINLARO™ (ixazomib) Improved Progression-Free Survival in Adult Patients with Multiple Myeloma Following Autologous Stem Cell Transplant –

– Data will be presented at the 60th American Society of Hematology (ASH) Annual Meeting on December 2, 2018 –